The last patient in the ALLEVIATE phase 3 trial of topical ocular reproxalap for allergic conjunctivitis has been dosed, Aldeyra Therapeutics announced.
The multicenter, double-masked, parallel-group, vehicle-controlled phase 3 clinical trial enrolled more than 300 patients who randomly received topical ocular 0.25% reproxalap, 0.5% reproxalap or vehicle. Patient-reported ocular itching is the primary outcome measure.
“Affecting approximately 20% of the population worldwide, allergic conjunctivitis is a common disease that can cause persistently disturbing symptoms and is often associated
Uncategorized